GLP-1 RA therapy's impact on osteosarcopenia in older diabetic women to be investigated

The prevalence of Type 2 diabetes mellitus is high among older adults, often necessitating complex multidrug regimens to achieve optimal glycemic control while minimizing adverse effects. While GLP-1 receptor agonists (GLP-1 RAs) are highly effective antihyperglycemic drugs, their specific impact on osteosarcopenia – the concurrent loss of muscle mass/strength (sarcopenia) and bone density (osteoporosis) – in this vulnerable population remains largely unexplored. This knowledge gap is critical, as both conditions significantly impair quality of life, increase frailty risks, and contribute to falls and fractures in older individuals with diabetes. Current standard-of-care often fails to address this dual burden comprehensively.

This study is designed to enroll older female adults, specifically those over 65 years of age with type 2 diabetes. Participants will receive GLP-1 RA therapy as part of their routine clinical care for a duration of 6 months. The primary endpoints include comprehensive muscle strength assessments, utilizing established measures such as hand grip strength and the Timed Up and Go test. Additionally, blood samples will be collected to analyze various bone turnover markers, and bone mineral density testing will be conducted to evaluate bone health. The central aim is to determine if this 6-month GLP-1 RA intervention influences muscle strength.